Paroxetine-d2

Paroxetine-d2 (CTP 347) is a deuterium labeled Paroxetine (HY-122272) . Paroxetine is an oral inhibitor that falls under the category of selective serotonin reuptake inhibitors (SSRIs) . Paroxetine is also a very weak norepinephrine (NE) reuptake inhibitor, capable of inducing cell apoptosis and having anti-tumor activity. Paroxetine has antidepressant, anti-anxiety, and pain-relieving effects, and it can help improve conditions like obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual anxiety, and chronic headaches[1][2][3][4].

Product Specifications

CAS Number

[923932-43-8]

Product Name Alternative

CTP 347; BRL29060-d2

UNSPSC

12352005

Target

Adrenergic Receptor; Apoptosis; Isotope-Labeled Compounds; P2X Receptor; Serotonin Transporter

Related Pathways

Apoptosis; GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling; Others

Field of Research

Cancer; Neurological Disease

Smiles

FC1=CC=C([C@H]2[C@H](COC3=CC=C(OC([2H])([2H])O4)C4=C3)CNCC2)C=C1

Molecular Formula

C19H18D2FNO3

Molecular Weight

331.38

References & Citations

[1]Young-Woo Cho, et al. Paroxetine Induces Apoptosis of Human Breast Cancer MCF-7 Cells through Ca2+-and p38 MAP Kinase-Dependent ROS Generation. Cancers (Basel) . 2019 Jan 9;11 (1) :64. |[2]Malek Zarei, et al. Paroxetine attenuates the development and existing pain in a rat model of neurophatic pain. Iran Biomed J. 2014;18 (2) :94-100. |[3]S Lightowler, et al. Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav. 1994 Oct;49 (2) :281-5. |[4]M Bourin, et al. Paroxetine: a review. CNS Drug Rev. Spring 2001;7 (1) :25-47.